Stock Analysis on Net
Stock Analysis on Net

Stryker Corp. (NYSE:SYK)

This company has been moved to the archive! The financial data has not been updated since April 29, 2022.

Analysis of Revenues 

Microsoft Excel

Revenues as Reported

Stryker Corp., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
MedSurg and Neurotechnology 9,538 8,345 8,475 — —
Orthopaedics and Spine 7,570 6,006 6,409 — —
Net sales 17,108 14,351 14,884 — —

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Revenue Overview
The overall net sales demonstrated a positive trend between 2019 and 2021. Starting from $14,884 million in 2019, sales slightly decreased to $14,351 million in 2020, followed by a notable recovery and increase to $17,108 million in 2021.
Segment: MedSurg and Neurotechnology
This segment exhibited a modest decline from 2020 to 2021, with revenues decreasing from $8,475 million to $8,345 million. However, the value rebounded in 2021 to $9,538 million, indicating a period of volatility but overall growth across the two years.
Segment: Orthopaedics and Spine
The Orthopaedics and Spine segment showed a decline from 2019 to 2020, with revenue decreasing from $6,409 million to $6,006 million. This was followed by a substantial increase to $7,570 million in 2021, mirroring recovery trends seen in the overall net sales figures.
Trends and Insights
Both key business segments experienced a dip in revenue in 2020, which coincides with global economic challenges during that period. Nevertheless, a strong rebound occurred in 2021, surpassing previous revenue peaks. This suggests effective strategic adjustments or market recovery in that timeframe. The combined growth in segments contributed to the overall increase in net sales from 2020 to 2021.